New🔥 #CSWG study: 🔑 messages:
1) most changes in clinical trajectories in CS patients occur within the first 6h of admission already (#goldenshift) ⏱️
2) phenotyping and SCAI staging can be combined to improve risk stratification!🎯
https://t.co/9rBetxxrU8
🚨Recently Published in #CardioOncology
Evaluation of a screening algorithm to detect cardiac amyloidosis in mild to severe aortic valve stenosis🫀
#OpenAccess
Read more➡️https://t.co/2LJaoxC6OJ @vofab@ICOSociety
In this multicenter European registry, those patients in mid stage but not those in early or late stage of Tricuspid Regurgitation disease, showed significant 1-year survival with #TTEER vs conservative management. 4-parameter easy score to identify them. Thanks to the authors.
Presented at #AHA24:
In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo. Full trial results: https://t.co/ib0n1GaRtR
Congratulations to @ElricZweck, #JacobMoller and team for their late breaking work on #AKI in #AMICS at #TCT2024 with a simultaneous publication in @CircAHA - https://t.co/jR0HR9AENo. I had the privilege of writing the editorial comment https://t.co/jR0HR9AENo. @BrownUnivHealth
🚨 MAJOR news in the #ATTR#amyloidosis world! Today the much-anticipated HELIOS-B results were presented @escardio & simultaneously published in @NEJM. The largest ATTR-CM trial published to date, testing #vutrisiran vs. placebo. Bottom line: Huge win for vutrisiran! Lowered CV events and All-Cause mortality in the overall population & as monotherapy. Now, let’s take a deep dive into the results… https://t.co/iCeK5liS2M
A herculean #cardioonc effort amongst experts in assembling this statement on the rapidly evolving landscape of CV toxicities in cancer immunotherapeutics.
Great resource to study more of what we don't know!
👏to colleagues and friends
@ESC_Journals
https://t.co/x0xSJ57hmw
1/2 Following the DANGER SHOCK trial demonstrating reduced mortality with Impella in cardiogenic shock, the independent DSMB of the RECOVER IV trial has strongly recommended the trial be discontinued because of lack of equipoise. Therefore, we are ceasing enrollment in the trial.
We are proud to announce that the cardiology team at @UniklinikDUS successfully performed the first interventional transfemoral tricuspid valve replacement this week! A huge thank you to the entire team!
💥Happy to share publication of pilot phase of our German Cardiac Arrest Registry (G-CAR):
https://t.co/VR0bqdvDR0
➡️ next step: assessment of PROs
🙏 Thanks to all the investigators!
#CardiacArrest#OHCA@DGK_AG3@AnneFreund3@thiele_holger @jochen_dutzmann @EPTIG